首页> 外文期刊>Kosuyolu Kalp Dergisi >Combined Value of Contrast-Induced Nephropathy and the CHA2DS2-VASc Score for Predicting Mortality in Patients with Acute Coronary Syndrome Who Were Undergoing Percutaneous Coronary Intervention
【24h】

Combined Value of Contrast-Induced Nephropathy and the CHA2DS2-VASc Score for Predicting Mortality in Patients with Acute Coronary Syndrome Who Were Undergoing Percutaneous Coronary Intervention

机译:造影剂肾病和CHA2DS2-VASc评分在接受经皮冠状动脉介入治疗的急性冠脉综合征患者中预测死亡率的综合价值

获取原文
           

摘要

Introduction: Both contrast-induced nephropathy (CIN) and CHA2DS2-VASc score have predictive value for mortality in patients with acute coronary syndrome (ACS) who underwent percutaneous coronary intervention (PCI), whereas the prognostic significance CHA2DS2-VASc of risk score combined with CIN remains unclear. This study was designed to explore the combined value of CIN and CHA2DS2-VASc score for predicting long-term mortality in these patients. Patients and Methods: This retrospective study included 1058 consecutive patients with ACS who were treated with PCI. CIN was defined as a serum creatinine increase ≥ 0.5 mg/dL or ≥ 25% within 48-72 hours after contrast exposure. The patients were divided into two groups, as survivors or nonsurvivors. Results: The CHA2DS2-VASc score and CIN were independently predictive for all-cause mortality (HR: 1.444, 95% CI: 1.327-1.572, p 0.001; HR: 1.850, 95% CI: 1.298-2.637, p= 0.001, respectively). Also, multivessel diseases, Killip ≥ 2, beta blockers, and ACE/ARB use at follow-up were independently risk factors for all- cause mortality. Adding CIN on top of the CHA2DS2-VASc score yielded superior risk-predictive capacity beyond CHA2DS2-VASc score alone [AUC: 0.735 (0.701-0.769)], which is shown by improved AUC [AUC: 0.754 (0.720-0.787, difference p= 0.0149)] as well as net reclassification improvement (NRI 28.5%, p 0.001) and integrated discrimination improvement (IDI 0.021, p 0.001). Conclusion: Our study demonstrated that combining the predictive value of CIN and the CHA2DS2-VASc score yielded a more accurate predictive value for long-term mortality in ACS patients who underwent PCI as compared to the CHA2DS2-VASc score alone.
机译:简介:造影剂肾病(CIN)和CHA2DS2-VASc评分均对经皮冠状动脉介入治疗(PCI)的急性冠状动脉综合征(ACS)患者的死亡率具有预测价值,而CHA2DS2-VASc风险评分与风险评分并重的预后意义CIN仍不清楚。本研究旨在探讨CIN和CHA2DS2-VASc评分的组合值,以预测这些患者的长期死亡率。患者和方法:这项回顾性研究包括1058例接受PCI治疗的ACS连续患者。 CIN定义为对比暴露后48-72小时内血清肌酐增加≥0.5 mg / dL或≥25%。将患者分为幸存者和非幸存者两类。结果:CHA2DS2-VASc得分和CIN可以独立预测全因死亡率(HR:1.444,95%CI:1.327-1.572,p <0.001; HR:1.850,95%CI:1.298-2.637,p = 0.001,分别)。同样,多支血管疾病,Killip≥2,β受体阻滞剂和随访时使用ACE / ARB是全因死亡率的独立危险因素。在CHA2DS2-VASc评分之上添加CIN可以产生优于单独的CHA2DS2-VASc评分的更高的风险预测能力[AUC:0.735(0.701-0.769)],这通过改善的AUC [AUC:0.754(0.720-0.787,差异p = 0.0149)]以及净重分类改进(NRI 28.5%,p <0.001)和综合区分度改进(IDI 0.021,p <0.001)。结论:我们的研究表明,与单独使用CHA2DS2-VASc评分相比,将CIN预测值与CHA2DS2-VASc评分相结合可得出接受PCI的ACS患者长期死亡率的更准确预测值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号